Compare NOV & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOV | DNTH |
|---|---|---|
| Founded | 1862 | 2015 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.5B |
| IPO Year | 1996 | 2018 |
| Metric | NOV | DNTH |
|---|---|---|
| Price | $21.14 | $115.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $19.47 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.5M | 774.0K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $8,744,000,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.81 | $29.48 |
| P/E Ratio | $412.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.09 | $20.31 |
| 52 Week High | $21.55 | $114.55 |
| Indicator | NOV | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 61.15 |
| Support Level | $18.03 | $79.27 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.71 | 5.91 |
| MACD | 0.14 | -0.05 |
| Stochastic Oscillator | 99.58 | 93.10 |
NOV (formerly National Oilwell Varco) designs, manufactures, and sells a wide range of equipment and components supplying the oil and gas industry, including rig equipment, downhole tools, drill pipe, and well casing. NOV's customers include major integrated oil companies, national oil companies, independent oil and gas companies, and drilling contractors. Its operations are organized into two reportable segments: energy products and services and energy equipment. NOV operates on a global scale, with international markets contributing nearly two-thirds of its annual revenue.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.